MX2023007559A - Formulaciones de peptidos terapeuticos. - Google Patents
Formulaciones de peptidos terapeuticos.Info
- Publication number
- MX2023007559A MX2023007559A MX2023007559A MX2023007559A MX2023007559A MX 2023007559 A MX2023007559 A MX 2023007559A MX 2023007559 A MX2023007559 A MX 2023007559A MX 2023007559 A MX2023007559 A MX 2023007559A MX 2023007559 A MX2023007559 A MX 2023007559A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic peptide
- peptide formulations
- pharmaceutical formulations
- stable pharmaceutical
- formulations
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Formulaciones farmacéuticas estables para el receptor terapéutico dual de GLP-1/agonistas del receptor de glucagón y métodos para usar tales formulaciones farmacéuticas estables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129157P | 2020-12-22 | 2020-12-22 | |
| PCT/US2021/064592 WO2022140373A1 (en) | 2020-12-22 | 2021-12-21 | Therapeutic peptide formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007559A true MX2023007559A (es) | 2023-07-11 |
Family
ID=79831433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007559A MX2023007559A (es) | 2020-12-22 | 2021-12-21 | Formulaciones de peptidos terapeuticos. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4267104A1 (es) |
| JP (1) | JP2024501256A (es) |
| KR (1) | KR20230124035A (es) |
| CN (1) | CN116635008A (es) |
| AR (2) | AR124464A1 (es) |
| AU (1) | AU2021409795A1 (es) |
| CA (1) | CA3200209A1 (es) |
| CL (1) | CL2023001854A1 (es) |
| CO (1) | CO2023008101A2 (es) |
| CR (1) | CR20230269A (es) |
| DO (1) | DOP2023000128A (es) |
| EC (1) | ECSP23046474A (es) |
| IL (1) | IL303914A (es) |
| MX (1) | MX2023007559A (es) |
| PE (1) | PE20240116A1 (es) |
| TW (1) | TW202239427A (es) |
| WO (1) | WO2022140373A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101121317B1 (ko) | 2003-08-12 | 2012-03-09 | 일라이 릴리 앤드 캄파니 | 기계적 확대율을 갖는 삼중 나사식 쓰레드를 갖는 약제투여 장치 |
| LT1732629T (lt) | 2004-03-30 | 2019-06-10 | Eli Lilly And Company | Vaistų dozavimo prietaisas su spyruokliniu fiksavimo elementu, kuris suveikia, įvedant paskutinę dozę |
| EA027032B1 (ru) | 2010-03-01 | 2017-06-30 | Эли Лилли Энд Компани | Автоматическое инъекционное устройство с замедлителем, включающим смещающий элемент с двойственной функцией |
| US10987505B2 (en) | 2012-03-07 | 2021-04-27 | Deka Products Limited Partnership | Infusion pump assembly |
| TWI783244B (zh) | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
-
2021
- 2021-12-21 WO PCT/US2021/064592 patent/WO2022140373A1/en active Application Filing
- 2021-12-21 IL IL303914A patent/IL303914A/en unknown
- 2021-12-21 PE PE2023001940A patent/PE20240116A1/es unknown
- 2021-12-21 EP EP21847606.7A patent/EP4267104A1/en active Pending
- 2021-12-21 AU AU2021409795A patent/AU2021409795A1/en active Pending
- 2021-12-21 TW TW110147980A patent/TW202239427A/zh unknown
- 2021-12-21 JP JP2023538073A patent/JP2024501256A/ja active Pending
- 2021-12-21 CA CA3200209A patent/CA3200209A1/en active Pending
- 2021-12-21 CR CR20230269A patent/CR20230269A/es unknown
- 2021-12-21 KR KR1020237024731A patent/KR20230124035A/ko active Search and Examination
- 2021-12-21 CN CN202180085734.2A patent/CN116635008A/zh active Pending
- 2021-12-21 AR ARP210103614A patent/AR124464A1/es unknown
- 2021-12-21 MX MX2023007559A patent/MX2023007559A/es unknown
-
2022
- 2022-12-02 AR ARP220103322A patent/AR127860A2/es unknown
-
2023
- 2023-06-20 CL CL2023001854A patent/CL2023001854A1/es unknown
- 2023-06-21 CO CONC2023/0008101A patent/CO2023008101A2/es unknown
- 2023-06-21 DO DO2023000128A patent/DOP2023000128A/es unknown
- 2023-06-21 EC ECSENADI202346474A patent/ECSP23046474A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022140373A1 (en) | 2022-06-30 |
| DOP2023000128A (es) | 2023-07-16 |
| PE20240116A1 (es) | 2024-01-22 |
| AR124464A1 (es) | 2023-03-29 |
| CN116635008A (zh) | 2023-08-22 |
| AU2021409795A1 (en) | 2023-06-29 |
| CL2023001854A1 (es) | 2024-02-16 |
| CA3200209A1 (en) | 2022-06-30 |
| EP4267104A1 (en) | 2023-11-01 |
| JP2024501256A (ja) | 2024-01-11 |
| CO2023008101A2 (es) | 2023-06-30 |
| TW202239427A (zh) | 2022-10-16 |
| IL303914A (en) | 2023-08-01 |
| ECSP23046474A (es) | 2023-07-31 |
| CR20230269A (es) | 2023-07-18 |
| KR20230124035A (ko) | 2023-08-24 |
| AR127860A2 (es) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230330A (es) | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso | |
| WO2012112626A3 (en) | Compositions, devices and methods of use thereof for the treatment of cancers | |
| MX2016010998A (es) | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. | |
| PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
| MX2019008006A (es) | Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco. | |
| PH12021550964A1 (en) | Protein tyrosine-tyrosine analogs and methods of using the same. | |
| BR112020005841A8 (pt) | Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas. | |
| MX2023005994A (es) | Composiciones de inhibidores peptidicos del receptor de interleucina-23. | |
| MX2020008387A (es) | Usos terapeuticos de agonistas glp1r. | |
| EA202091464A1 (ru) | Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита | |
| MX2021009851A (es) | Formulacion de anticuerpos terapeuticos. | |
| CR20230269A (es) | Formulaciones de péptidos terapéuticos | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| MX2020005117A (es) | Formulaciones peptídicas de liberación sostenida. | |
| CR20220046A (es) | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 | |
| MX2023002889A (es) | Formulaciones de anticuerpos terapeuticos. | |
| EA202191511A1 (ru) | Составы на основе аналога пептида оксинтомодулина | |
| CR20220591A (es) | Composiciones y métodos para suministrar agentes farmacéuticamente activos | |
| MX2022016012A (es) | Polipéptidos de unión al receptor de la il-23 humana. | |
| MX2022016478A (es) | Administracion del antagonista de cebp-beta y metodos de uso. | |
| MX2023005030A (es) | Proteinas de fusion para el tratamiento de enfermedades. | |
| MX2022014670A (es) | Formulacion liquida. | |
| WO2024020361A3 (en) | Inhalable serotonin receptor agonist formulations | |
| EA202191288A1 (ru) | Cholix-производные носители для пероральной доставки гетерологичной полезной нагрузки | |
| MX2023005042A (es) | Terapia basada en oligonucleótidos y usos de la misma. |